SMi offer sponsorship, advertising and branding packages, uniquely tailored to compliment your company's marketing strategy.
Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry.
Paediatric drug development has become an essential part of drug development in general. A first paediatric pharmaceutical legislation came in force in the USA in 1997,
followed by the EU paediatric regulation in force since 2007. Without a Paediatric Investigation Plan (PIP) approved by the EMA paediatric committee, no new drug can be approved in the EU.